Idenix Pharmaceuticals Inc: (NASD: IDIX)
$4.17
0.27 (6.92%)
Volume 3,052,935
May 17 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 3.81 - 4.19 |
| 52wk Low - High | 3.21 - 11.30 |
| Previous Close | 3.90 |
| Avg. Volume | 682,725 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 558.60 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.55 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.87 |
| Quarterly Earnings ESP |
-4.55% |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
91 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.87 |
| Current Quarter Estimate | -0.22 |
| Most Accurate Estimate | -0.23 |
| Earnings ESP |
-4.55% |
| Next Earnings Report Date | 08-07-2013 |
| EPS Last Year | -0.60 |
| Expected Earnings Growth | NA |
Company Description
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and human immunodeficiency virus.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.22 | -0.23 | -0.87 | -0.78 |
| Number of Estimates | 8 | 8 | 11 | 12 |
| Low Estimate | -0.26 | -0.32 | -1.07 | -1.23 |
| High Estimate | -0.18 | -0.18 | -0.72 | NA |
| Year Ago EPS | -0.23 | 0.03 | -0.23 | -0.87 |
| EPS Growth | 3.26% | -870.83% | -278.26% | 10.92% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| IDENIX PHARMA | IDIX | 4.17 | |
|
| AETERNA ZENTARS | AEZS | 2.10 | |
|
| ANIKA THERAPEUT | ANIK | 14.40 | |
|
| GENTIUM SPA-ADR | GENT | 8.87 | |
|
| AASTROM BIOSCI | ASTM | 0.57 | |
|
| ACHILLION PHARM | ACHN | 7.77 | |
|
| ADDEX THERA LTD | ADDXF | 6.94 | |
|
| AFFYMAX INC | AFFY | 1.33 | |
|
| ALEXION PHARMA | ALXN | 102.90 | |
|
| ALKERMES INC | ALKS | 31.69 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Setback for Idenix Pharma
Mar 28, 2013
Idenix Reports In-Line 4Q Loss
Mar 01, 2013
Pipeline Setback for Idenix
Feb 07, 2013
Abbott Reports Encouraging HCV Data
Oct 16, 2012
Idenix's Candidate on Clinical Hold
Aug 30, 2012
Bad News for Bristol-Myers
Aug 27, 2012
Pipeline Setback at Idenix
Aug 20, 2012
Company News for June 21, 2012
Jun 21, 2012
Financials
| EPS TTM | -0.60 |
| Sales | 70 |
| Net Income | -75 |
| Price/Earnings | NA |
| Price/Book | 2.96 |
| Price/Cash Flow | NA |
| Price/Sales | 16.02 |
News
Seth Klarman Buys BP, AIG, Elan Corp, Sells News Corp., Oracle - GuruFocus
May 14, 2013
Idenix Pharmaceuticals reports net loss for Q1 - Datamonitor
May 13, 2013
The Far-Off Four, 52-week Lows Held by Gurus - GuruFocus
May 11, 2013
IDIX, YAVY, CVGI, HBIO, CYAN, OVRL Are Seasonally Ripe To Go Down In the Next Five Weeks - M2
May 10, 2013
Idenix Pharmaceuticals to Present at Three Upcoming Healthcare Conferences - Globenewswire
May 8, 2013
Numbers for the Day - GuruFocus
May 8, 2013
Idenix Pharmaceuticals reports encouraging data from hepatitis C virus trial - Datamonitor
May 3, 2013
Idenix Pharmaceuticals Inc dips to net loss of USD30.8m in Q1 2013 - M2
May 1, 2013
Broker Recommendations
| Current ABR | 2.25 |
| ABR (Last Week) | 2.25 |
| # of recs in ABR | 12 |
| Average Target Price | 5.90 |
| Industry Rank by ABR | 91 out of 265 |
| Rank in Industry | 36 out of 155 |
